Tritanrix-HepB/Hib-MenAC

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline

Conditions

DiphtheriaDiphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis VaccinHaemophilus Influenzae Type bHepatitis BTetanusWhole Cell Pertussis

Phase 3

Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m

CompletedNCT00136604

GlaxoSmithKlineDiphtheria, Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin, Haemophilus Influenzae Type b +3

Start: 2006-01-22End: 2006-04-23Updated: 2020-02-20

Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children

CompletedNCT00228917

GlaxoSmithKlineDiphtheria, Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus Influenzae Type b-Neisseria Meningitidis Vaccin, Haemophilus Influenzae Type b +3

Start: 2005-06-16End: 2006-01-20Updated: 2020-02-20